The benefit of STent placement and blood pressure and lipid-lowering for the prevention of progression of renal dysfunction caused by Atherosclerotic ostial stenosis of the Renal artery. The STAR-study: rationale and study design

Liesbeth Bax; Willem P. Th M. Mali; Erik Buskens; Hein A. Koomans; J. J. Beutler; B. Braam; F. J. A. Beek; T. J. Rabelink; C. T. Postma; F. T. M. Huysmans; J. Deinum; Th Thien; L. J. Schultze Kool; A. J. J. Woittiez; J. J. Kouwenberg; A. H. van den Meiracker; P. M. T. Pattynama; P. J. G. van de Ven; D. Vroegindeweij; C. J. Doorenbos; J. C. N. M. Aarts; A. A. Kroon; P. W. de Leeuw; M. W. de Haan; J. M. A. van Engelshoven; M. J. C. M. Rutten; G. A. van Montfrans; J. A. Reekers; P. F. Plouin; A. La Batide Alanore; M. Azizi; A. Raynaud; P. N. Harden; M. Cowling

The benefit of STent placement and blood pressure and lipid-lowering for the prevention of progression of renal dysfunction caused by Atherosclerotic ostial stenosis of the Renal artery. The STAR-study: rationale and study design

Liesbeth Bax, Willem P. Th M. Mali, Erik Buskens, Hein A. Koomans, J. J. Beutler, B. Braam, F. J. A. Beek, T. J. Rabelink, C. T. Postma, F. T. M. Huysmans, J. Deinum, Th Thien, L. J. Schultze Kool, A. J. J. Woittiez, J. J. Kouwenberg, A. H. van den Meiracker, P. M. T. Pattynama, P. J. G. van de Ven, D. Vroegindeweij, C. J. DoorenbosJ. C. N. M. Aarts, A. A. Kroon, P. W. de Leeuw, M. W. de Haan, J. M. A. van Engelshoven, M. J. C. M. Rutten, G. A. van Montfrans, J. A. Reekers, P. F. Plouin, A. La Batide Alanore, M. Azizi, A. Raynaud, P. N. Harden, M. Cowling

Research output: Contribution to journal › Article › Academic › peer-review

86 Citations (Scopus)

Abstract

BACKGROUND: Atherosclerotic renal artery stenosis (ARAS) is associated with progressive loss of renal function and is one of the most important causes of renal failure in the elderly. Current treatment includes restoration of the renal arterial lumen by endovascular stent placement. However, this treatment only affects damage caused by ARAS due to the stenosis and ensuing post-stenotic ischemia. ARAS patients have severe general vascular disease. Atherosclerosis and hypertension can also damage the kidney parenchyma causing renal failure. Medical treatment focuses on the latter. Lipid-lowering drugs (statins) could reduce renal failure progression and could reduce the overall high cardiovascular risk. The additional effect on preserving renal function of stent placement as compared to medical therapy alone is unknown. Therefore, the STAR-study aims to compare the effects of renal artery stent placement together with medication vs. medication alone on renal function in ARAS patients. METHOD: Patients with an ARAS of > or = 50% and renal failure (creatinine (Cr) clearance < 80 mL/min/1.73 m2) are randomly assigned to stent placement with medication or to medication alone. Medication consists of statins, anti-hypertensive drugs and antiplatelet therapy. Patients are followed for 2 yrs with extended follow-up to 5 yrs. The primary outcome of this study is a reduction in Cr clearance > 20% compared to baseline. This trial will include 140 patients

Original language	English
Pages (from-to)	807-812
Journal	Journal of nephrology
Volume	16
Issue number	6
Publication status	Published - 2003

Cite this

Bax, L., Mali, W. P. T. M., Buskens, E., Koomans, H. A., Beutler, J. J., Braam, B., Beek, F. J. A., Rabelink, T. J., Postma, C. T., Huysmans, F. T. M., Deinum, J., Thien, T., Schultze Kool, L. J., Woittiez, A. J. J., Kouwenberg, J. J., van den Meiracker, A. H., Pattynama, P. M. T., van de Ven, P. J. G., Vroegindeweij, D., ... Cowling, M. (2003). The benefit of STent placement and blood pressure and lipid-lowering for the prevention of progression of renal dysfunction caused by Atherosclerotic ostial stenosis of the Renal artery. The STAR-study: rationale and study design. Journal of nephrology, 16(6), 807-812.

@article{5ad7b1bacab24408bad12530e75e0dd1,

title = "The benefit of STent placement and blood pressure and lipid-lowering for the prevention of progression of renal dysfunction caused by Atherosclerotic ostial stenosis of the Renal artery. The STAR-study: rationale and study design",

abstract = "BACKGROUND: Atherosclerotic renal artery stenosis (ARAS) is associated with progressive loss of renal function and is one of the most important causes of renal failure in the elderly. Current treatment includes restoration of the renal arterial lumen by endovascular stent placement. However, this treatment only affects damage caused by ARAS due to the stenosis and ensuing post-stenotic ischemia. ARAS patients have severe general vascular disease. Atherosclerosis and hypertension can also damage the kidney parenchyma causing renal failure. Medical treatment focuses on the latter. Lipid-lowering drugs (statins) could reduce renal failure progression and could reduce the overall high cardiovascular risk. The additional effect on preserving renal function of stent placement as compared to medical therapy alone is unknown. Therefore, the STAR-study aims to compare the effects of renal artery stent placement together with medication vs. medication alone on renal function in ARAS patients. METHOD: Patients with an ARAS of > or = 50% and renal failure (creatinine (Cr) clearance < 80 mL/min/1.73 m2) are randomly assigned to stent placement with medication or to medication alone. Medication consists of statins, anti-hypertensive drugs and antiplatelet therapy. Patients are followed for 2 yrs with extended follow-up to 5 yrs. The primary outcome of this study is a reduction in Cr clearance > 20% compared to baseline. This trial will include 140 patients",

author = "Liesbeth Bax and Mali, {Willem P. Th M.} and Erik Buskens and Koomans, {Hein A.} and Beutler, {J. J.} and B. Braam and Beek, {F. J. A.} and Rabelink, {T. J.} and Postma, {C. T.} and Huysmans, {F. T. M.} and J. Deinum and Th Thien and {Schultze Kool}, {L. J.} and Woittiez, {A. J. J.} and Kouwenberg, {J. J.} and {van den Meiracker}, {A. H.} and Pattynama, {P. M. T.} and {van de Ven}, {P. J. G.} and D. Vroegindeweij and Doorenbos, {C. J.} and Aarts, {J. C. N. M.} and Kroon, {A. A.} and {de Leeuw}, {P. W.} and {de Haan}, {M. W.} and {van Engelshoven}, {J. M. A.} and Rutten, {M. J. C. M.} and {van Montfrans}, {G. A.} and Reekers, {J. A.} and Plouin, {P. F.} and {La Batide Alanore}, A. and M. Azizi and A. Raynaud and Harden, {P. N.} and M. Cowling",

year = "2003",

language = "English",

volume = "16",

pages = "807--812",

journal = "Journal of nephrology",

issn = "1121-8428",

publisher = "Wichtig Publishing",

number = "6",

}

Bax, L, Mali, WPTM, Buskens, E, Koomans, HA, Beutler, JJ, Braam, B, Beek, FJA, Rabelink, TJ, Postma, CT, Huysmans, FTM, Deinum, J, Thien, T, Schultze Kool, LJ, Woittiez, AJJ, Kouwenberg, JJ, van den Meiracker, AH, Pattynama, PMT, van de Ven, PJG, Vroegindeweij, D, Doorenbos, CJ, Aarts, JCNM, Kroon, AA, de Leeuw, PW, de Haan, MW, van Engelshoven, JMA, Rutten, MJCM, van Montfrans, GA, Reekers, JA, Plouin, PF, La Batide Alanore, A, Azizi, M, Raynaud, A, Harden, PN & Cowling, M 2003, 'The benefit of STent placement and blood pressure and lipid-lowering for the prevention of progression of renal dysfunction caused by Atherosclerotic ostial stenosis of the Renal artery. The STAR-study: rationale and study design', Journal of nephrology, vol. 16, no. 6, pp. 807-812.

The benefit of STent placement and blood pressure and lipid-lowering for the prevention of progression of renal dysfunction caused by Atherosclerotic ostial stenosis of the Renal artery. The STAR-study: rationale and study design. / Bax, Liesbeth; Mali, Willem P. Th M.; Buskens, Erik et al.
In: Journal of nephrology, Vol. 16, No. 6, 2003, p. 807-812.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - The benefit of STent placement and blood pressure and lipid-lowering for the prevention of progression of renal dysfunction caused by Atherosclerotic ostial stenosis of the Renal artery. The STAR-study: rationale and study design

AU - Bax, Liesbeth

AU - Mali, Willem P. Th M.

AU - Buskens, Erik

AU - Koomans, Hein A.

AU - Beutler, J. J.

AU - Braam, B.

AU - Beek, F. J. A.

AU - Rabelink, T. J.

AU - Postma, C. T.

AU - Huysmans, F. T. M.

AU - Deinum, J.

AU - Thien, Th

AU - Schultze Kool, L. J.

AU - Woittiez, A. J. J.

AU - Kouwenberg, J. J.

AU - van den Meiracker, A. H.

AU - Pattynama, P. M. T.

AU - van de Ven, P. J. G.

AU - Vroegindeweij, D.

AU - Doorenbos, C. J.

AU - Aarts, J. C. N. M.

AU - Kroon, A. A.

AU - de Leeuw, P. W.

AU - de Haan, M. W.

AU - van Engelshoven, J. M. A.

AU - Rutten, M. J. C. M.

AU - van Montfrans, G. A.

AU - Reekers, J. A.

AU - Plouin, P. F.

AU - La Batide Alanore, A.

AU - Azizi, M.

AU - Raynaud, A.

AU - Harden, P. N.

AU - Cowling, M.

PY - 2003

Y1 - 2003

N2 - BACKGROUND: Atherosclerotic renal artery stenosis (ARAS) is associated with progressive loss of renal function and is one of the most important causes of renal failure in the elderly. Current treatment includes restoration of the renal arterial lumen by endovascular stent placement. However, this treatment only affects damage caused by ARAS due to the stenosis and ensuing post-stenotic ischemia. ARAS patients have severe general vascular disease. Atherosclerosis and hypertension can also damage the kidney parenchyma causing renal failure. Medical treatment focuses on the latter. Lipid-lowering drugs (statins) could reduce renal failure progression and could reduce the overall high cardiovascular risk. The additional effect on preserving renal function of stent placement as compared to medical therapy alone is unknown. Therefore, the STAR-study aims to compare the effects of renal artery stent placement together with medication vs. medication alone on renal function in ARAS patients. METHOD: Patients with an ARAS of > or = 50% and renal failure (creatinine (Cr) clearance < 80 mL/min/1.73 m2) are randomly assigned to stent placement with medication or to medication alone. Medication consists of statins, anti-hypertensive drugs and antiplatelet therapy. Patients are followed for 2 yrs with extended follow-up to 5 yrs. The primary outcome of this study is a reduction in Cr clearance > 20% compared to baseline. This trial will include 140 patients

AB - BACKGROUND: Atherosclerotic renal artery stenosis (ARAS) is associated with progressive loss of renal function and is one of the most important causes of renal failure in the elderly. Current treatment includes restoration of the renal arterial lumen by endovascular stent placement. However, this treatment only affects damage caused by ARAS due to the stenosis and ensuing post-stenotic ischemia. ARAS patients have severe general vascular disease. Atherosclerosis and hypertension can also damage the kidney parenchyma causing renal failure. Medical treatment focuses on the latter. Lipid-lowering drugs (statins) could reduce renal failure progression and could reduce the overall high cardiovascular risk. The additional effect on preserving renal function of stent placement as compared to medical therapy alone is unknown. Therefore, the STAR-study aims to compare the effects of renal artery stent placement together with medication vs. medication alone on renal function in ARAS patients. METHOD: Patients with an ARAS of > or = 50% and renal failure (creatinine (Cr) clearance < 80 mL/min/1.73 m2) are randomly assigned to stent placement with medication or to medication alone. Medication consists of statins, anti-hypertensive drugs and antiplatelet therapy. Patients are followed for 2 yrs with extended follow-up to 5 yrs. The primary outcome of this study is a reduction in Cr clearance > 20% compared to baseline. This trial will include 140 patients

M3 - Article

C2 - 14736007

SN - 1121-8428

VL - 16

SP - 807

EP - 812

JO - Journal of nephrology

JF - Journal of nephrology

IS - 6

ER -